Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-Ethyl-5-[9-(3-methoxypropyl)-9H-carbazol-2-yl]pyrimidine-2,4-diamine is an experimental small molecule belonging to the class of carbazole-containing pyrimidines. It has been described as a diaminopyrimidine renin inhibitor compound and is structurally related to other pyrimidine-based inhibitors. The primary mechanism of action is believed to be inhibition of renin, a key enzyme in the renin–angiotensin system that regulates blood pressure and fluid balance. This compound has been studied primarily in biochemical assays for its potential as a renin inhibitor but does not have clinical approval or established therapeutic indications[1][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-ethyl-5-[9-(3-methoxypropyl)-9H-carbazol-2-yl]pyrimidine-2,4-diamine.